At Kinzbio, we develop phage-based therapies and preventive solutions to treat bacterial infections in humans, particularly those caused by antibiotic-resistant bacteria. Our platform enables us to deliver high-quality, personalized therapies within 5–15 days, tailored to the specific bacterium causing the patient’s infection
| Website | http://kinzbio.com |
| Employees | 13 (10 on RocketReach) |
| Founded | 2021 |
| Industry | Biotechnology Research |
| Keywords | Biotechnology, Microbial Technology, Phage Therapy, Phage Research, Antibacterial Solutions, Biocontrol, Scientific Research, Bacteria Control, Health Solutions, Animal Health Solutions, Microbial Control, Environmental Sustainability, Sustainable Solutions, Innovative Solutions, Food Safety Solutions |
| Competitors | Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, Bio-Rad Laboratories, MilliporeSigma, DNANUDGE, Zymergen, Inc., Receptos, a wholly-owned subsidiary of Celgene, Twist Bioscience +39 more (view full list) |
Looking for a particular Kinzbio employee's phone or email?
Gregorio Iraola is the CEO of Kinzbio.
10 people are employed at Kinzbio.
Kinzbio is based in Montevideo, Montevideo Department.